Key takeaways
- Dividend income crosses the border: US dividend stocks give Canadian investors access to sectors and business models that simply don’t exist on the TSX, from specialty insurance to semiconductor manufacturing to biotech, and many of these companies are growing their payouts at a pace most Canadian dividend payers can’t match.
- Growth and income aren’t exclusive: The standout names on this list aren’t just paying dividends for the sake of it. They’re backed by real earnings momentum in areas like cloud networking, gold mining, and electric vehicle infrastructure, meaning you’re not sacrificing capital appreciation potential just to collect a quarterly cheque.
- Watch withholding taxes and volatility: Canadians buying US dividend stocks face a 15% withholding tax in registered accounts like TFSAs (RRSPs get a treaty exemption), which eats into your yield. On top of that, some of these sectors, particularly gold miners and smaller industrial names, can swing hard on commodity prices or shifting government policy, so position sizing matters more than usual.
Canadian investors tend to default to the TSX for dividend income. Makes sense. The Big 6 banks, pipelines, telecoms, utilities. They’re familiar, they pay well, and the dividend tax credit makes them efficient in taxable accounts. I get the appeal. I own plenty of Canadian dividend payers myself.
But that comfort zone comes with a cost. You’re concentrating in a handful of sectors on a relatively small exchange. Financials and energy alone make up a massive chunk of the TSX. If you want exposure to things like cybersecurity, specialty finance, or next-generation pharma, you pretty much have to look south of the border.
That’s where this list comes in. I went looking for quality companies trading on U.S. exchanges that pay dividends and bring something different to a Canadian portfolio. Not just yield for yield’s sake. I wanted businesses with real earnings growth, competitive moats, and dividends that are actually supported by cash flow. A 5% yield means nothing if the payout ratio is 120% and the balance sheet is deteriorating.
Some of these names will surprise you. A few aren’t traditional “dividend stocks” at all. They’re growth companies that happen to have initiated payouts recently, which I actually find more interesting than a mature business grinding out 2% annual dividend bumps. A company that starts paying a dividend because it’s generating so much free cash it doesn’t know what else to do with it? That’s a good signal.
One thing to keep in mind: U.S. dividends are taxed differently for Canadians. You won’t get the dividend tax credit, and there’s a 15% withholding tax unless you hold these in an RRSP, where the Canada-U.S. tax treaty shelters you. Account placement matters here more than most people realize.
With that context, I focused on ten names spanning very different industries, each with a specific reason I think they’re worth owning heading into 2026.
In This Article
- Bristol-Myers Squibb Company (BMY)
- Altria Group, Inc. (MO)
- PepsiCo, Inc. (PEP)
- Verizon Communications Inc. (VZ)
- Medtronic plc (MDT)
- Brookfield Asset Management Ltd. (BAM)
- The Progressive Corporation (PGR)
- Chevron Corporation (CVX)
- International Business Machines Corporation (IBM)
- Duke Energy Corporation (DUK)
Bristol-Myers Squibb Company (NYSE: BMY)
$62.09
Overall Grade7.2 / 10
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, and markets prescription medicines for serious diseases. The company focuses on key therapeutic areas including oncology, hematology, immunology, and cardiovascular disease...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E17.0
P/B6.2
P/S2.6
P/FCF10.4
FCF Yield+9.6%
Growth & Outlook
Rev Growth (YoY)+0.6%
EPS Growth (YoY)+2.9%
Revenue 5yr+0.9%
EPS 5yr+2.7%
FCF 5yr-19.4%
Fundamentals
Market Cap$126.8B
Dividend Yield4.1%
Operating Margin+20.5%
ROE+37.7%
Interest Coverage-
Competitive Edge
- Eliquis co-promotion with Pfizer creates a unique distribution advantage in anticoagulants, with switching costs embedded in physician prescribing habits and patient INR management protocols. Generic entry faces complex formulation and regulatory hurdles.
- BMY's immuno-oncology franchise (Opdivo, Yervoy) benefits from expanding label indications and combination regimens. Each new indication creates clinical data that reinforces physician adoption, building a compounding evidence moat.
- The Celgene acquisition brought Revlimid's cash flows and, critically, the CAR-T platforms (Abecma, Breyanzi) that position BMY in next-generation cell therapy, a market with high barriers to entry due to manufacturing complexity.
- BMY's cardiovascular and immunology pipeline (milvexian, cendakimab) targets large addressable markets. Milvexian as a Factor XIa inhibitor could be a differentiated anticoagulant with lower bleeding risk, a genuine clinical advance over current standards.
- Regulatory capture through decades of FDA engagement gives BMY institutional knowledge in navigating approval pathways. This is a durable but invisible advantage that reduces development timelines and increases probability of approval versus smaller competitors.
By the Numbers
- Forward P/E of 9.7x vs trailing 17.4x implies consensus expects EPS to nearly double from $3.46 to $6.34, and the PEG of 0.12 suggests the market is dramatically underpricing that earnings inflection relative to growth.
- FCF margin of 24.6% significantly exceeds net margin of 15.0%, with FCF-to-net-income conversion at 1.64x. This signals high earnings quality, as cash generation substantially outpaces reported profits, likely due to large non-cash amortization of acquired intangibles.
- FCF payout ratio of 42.7% vs earnings payout ratio of 69.7% reveals the dividend is far more secure than the income statement suggests. The gap reflects heavy intangible amortization depressing GAAP earnings while cash flow remains strong.
- Total shareholder yield of 13.1% is exceptional, driven primarily by 9.0% debt paydown yield. Management is aggressively deleveraging from the Celgene acquisition, which directly reduces equity risk and improves the capital structure.
- R&D spending at 28.8% of revenue ($13.9B) is among the highest in large-cap pharma, funding pipeline replenishment against upcoming LOEs. This is not discretionary cost but essential investment that the 24.6% FCF margin still comfortably supports.
Risk Factors
- Analyst revenue estimates project a decline from $47.4B (Y1) to $36.8B (Y5), a 22% cumulative drop. This reflects the Eliquis and Opdivo patent cliff, and the Growth grade of 3.5/10 confirms the market sees this as a structurally shrinking top line.
- FCF has deteriorated sharply: 3-year CAGR of -28.1% and 5-year CAGR of -19.4%. Even with strong current FCF margins, the trajectory is clearly negative, and the -40.1% YoY FCF decline in the most recent period is alarming.
- Net debt of $34B at 2.5x EBITDA with a Debt grade of 3.0/10 is concerning given the revenue cliff ahead. As EBITDA contracts with patent expirations, this leverage ratio will mechanically worsen unless debt paydown accelerates.
- Tangible book value per share is negative at -$9.76, with intangibles comprising 46.2% and goodwill 25.1% of total assets. This $62 stock is entirely supported by earnings power from assets that face binary pipeline and patent risk.
- EPS estimates decline from $6.34 (Y1) to $4.78 (Y5), a 25% erosion. The current forward P/E of 9.7x looks cheap until you realize you are buying a declining earnings stream, not a stable one.
Altria Group, Inc. (NYSE: MO)
$72.99
Overall Grade7.1 / 10
Altria Group, Inc. operates through several subsidiaries, including Philip Morris USA, U.S...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E13.8
P/B-34.3
P/S5.4
P/FCF12.8
FCF Yield+7.8%
Growth & Outlook
Rev Growth (YoY)+1.2%
EPS Growth (YoY)+16.0%
Revenue 5yr-0.7%
EPS 5yr+29.0%
FCF 5yr+1.5%
Fundamentals
Market Cap$121.9B
Dividend Yield5.8%
Operating Margin+54.3%
ROE-243.6%
Interest Coverage10.3x
Competitive Edge
- Marlboro commands ~42% of U.S. premium cigarette share, creating distribution lock-in at retail. Convenience stores allocate shelf space based on Marlboro velocity, giving Altria structural advantages in trade promotion and placement.
- NJOY holds one of only a handful of FDA-authorized ENDS (electronic nicotine delivery system) marketing orders. This regulatory moat effectively blocks most competitors from legally marketing flavored or novel vapor products in the U.S.
- The Master Settlement Agreement and federal excise tax structure create a regulatory barrier that protects incumbents. New cigarette entrants face per-stick cost disadvantages of $0.40 or more versus established manufacturers.
- Altria's direct store delivery network for smokeable products is nearly impossible to replicate. This distribution infrastructure gives new products like on! and NJOY immediate access to 200,000+ retail locations without incremental fixed cost.
By the Numbers
- FCF-to-net-income conversion of 1.07x confirms earnings quality is genuine, not accounting-driven. With capex at just 3% of operating cash flow, virtually all cash generated drops to shareholders. This is a textbook cash cow.
- Smokeable products operating income grew 1.5% YoY on revenue that declined 3.4%, meaning pricing power expanded operating margins by roughly 250bps. Altria is shrinking its way to higher profits per stick, a rare and powerful dynamic.
- Total shareholder yield of 7.9% (6.3% dividend + 0.8% buyback + 1.4% debt paydown) is among the highest in Consumer Staples. The three-pronged return structure gives management flexibility to shift allocation as conditions change.
- Oral tobacco operating income surged 26.2% YoY after a 15.9% decline the prior year, signaling the on! investment phase is maturing. The segment's operating margin jumped from ~52% to ~65%, approaching the smokeable segment's profitability.
- ROIC of 27.9% against a cost of debt implied at roughly 9.5% (interest coverage of 10.5x on $24.6B debt) creates massive economic value added. The spread between returns and capital cost is wider than most consumer staples peers.
Risk Factors
- Marlboro shipment volumes declined 12.2% YoY in FY2025, accelerating from the 9% decline in FY2024. This is the steepest volume erosion in the dataset, and pricing power must offset an increasingly steep hill each year.
- Discount cigarette shipments surged 41.3% YoY after three consecutive years of 18-30% declines. This reversal suggests trade-down pressure from consumers or competitive repositioning that could compress blended revenue per stick.
- The 'Other Operating Income' line ballooned to negative $2.5B in FY2025 from negative $414M in FY2024. This likely reflects NJOY-related impairments or restructuring charges, masking the true cost of the smoke-free transition.
- Negative book value of negative $1.91 per share and negative tangible book of negative $12.43 per share means the entire equity cushion has been consumed by buybacks and write-downs. Any large impairment directly threatens debt covenants.
- on! shipment volume growth decelerated sharply from 40.2% in FY2024 to 10.9% in FY2025, and the most recent quarter showed a 19% QoQ decline. The growth engine in oral nicotine may be plateauing earlier than bulls expect.
PepsiCo, Inc. (NASDAQ: PEP)
$136.64
Overall Grade6.4 / 10
PepsiCo, Inc. is a multinational food, snack, and beverage corporation headquartered in Purchase, New York...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E18.9
P/B8.9
P/S2.0
P/FCF21.2
FCF Yield+4.7%
Growth & Outlook
Rev Growth (YoY)+3.2%
EPS Growth (YoY)+27.2%
Revenue 5yr+4.0%
EPS 5yr+6.8%
FCF 5yr+5.1%
Fundamentals
Market Cap$186.5B
Dividend Yield4.3%
Operating Margin+14.8%
ROE+49.1%
Interest Coverage12.7x
Competitive Edge
- PepsiCo's dual snack-and-beverage model creates unique cross-selling leverage with retailers that neither Coca-Cola nor Mondelez can replicate. Shared DSD distribution and shelf-space negotiation across Frito-Lay and Pepsi beverages creates structural cost advantages.
- The FY2025 segment reorganization (merging Frito-Lay and Quaker into PFNA, creating IB Franchise) signals management is shifting toward an asset-light franchise model internationally, which should improve capital efficiency and reduce emerging market operational risk over time.
- Frito-Lay's 60%+ share of the U.S. salty snack market creates near-monopolistic pricing power and retailer dependency. Private label penetration in snacks remains far lower than in beverages, protecting this profit engine.
- GLP-1 drug adoption may actually benefit PepsiCo's snack portfolio more than harm it, as portion-controlled and protein-rich reformulations (Quaker, baked varieties) align with post-GLP-1 dietary patterns better than sugary beverages.
By the Numbers
- Forward P/E of 7.05x vs trailing 17.75x implies consensus expects EPS to nearly double from $1.13 trailing to $8.55 estimated Y1, suggesting the trailing figure is depressed by one-time charges from the segment reorganization, not structural earnings weakness.
- FCF conversion is healthy at 88% of net income with SBC at just 0.33% of revenue, meaning almost none of the reported earnings quality is eroded by non-cash compensation. This is exceptionally clean for a $185B market cap company.
- Negative cash conversion cycle of -108 days means PepsiCo collects cash and turns inventory far before paying suppliers (DPO of 206 days vs DIO+DSO of 99 days). This working capital advantage effectively finances operations with vendor capital.
- International Beverages Franchise segment operating profit surged 21% YoY on just 2.4% revenue growth, implying massive margin expansion. At 35.4% operating margin ($1.77B on $5B revenue), this asset-light franchise model is the highest-quality segment.
- ROIC of 13% against a weighted average cost of capital likely near 7-8% indicates genuine economic value creation, and the 49% ROE is partially leverage-amplified (2.4x D/E) but still reflects strong underlying asset productivity at 10.5% ROA.
Risk Factors
- PBNA operating profit collapsed 52.7% YoY to $1.09B despite 1.5% revenue growth, dropping segment margins from 8.3% to 3.9%. This is PepsiCo's largest revenue segment at $28.2B, so margin compression here overwhelms gains elsewhere.
- Total organic volume declined 2% for the second consecutive year while net pricing contributed +4%, meaning PepsiCo is still trading volume for price. PBNA volumes are down 3.5% and PFNA down 2%, both core North American businesses losing unit demand.
- FCF payout ratio at 84% leaves minimal cushion for the $5.71/share dividend. With net debt of $42.5B (2.27x EBITDA) and a current ratio below 1.0 at 0.93, the balance sheet has limited flexibility if earnings disappoint.
- Tangible book value per share is negative at -$8.88, with intangibles and goodwill comprising 30.5% and 17% of total assets respectively. This acquisition-heavy balance sheet carries impairment risk if brand values deteriorate in a volume-declining environment.
- EMEA organic volume flipped from +2% in FY2024 to -3% in FY2025 despite 8.2% reported revenue growth, meaning nearly all growth came from pricing and FX. This pricing-over-volume pattern across multiple geographies is unsustainable.
Verizon Communications Inc. (NYSE: VZ)
$46.38
Overall Grade6.2 / 10
Verizon Communications Inc. is a global leader in delivering communications, technology, information, and entertainment products and services...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E12.2
P/B2.0
P/S1.5
P/FCF10.3
FCF Yield+9.7%
Growth & Outlook
Rev Growth (YoY)+0.7%
EPS Growth (YoY)+1.0%
Revenue 5yr+0.8%
EPS 5yr-5.1%
FCF 5yr-2.1%
Fundamentals
Market Cap$177.3B
Dividend Yield6.1%
Operating Margin+21.2%
ROE+16.9%
Interest Coverage4.2x
Competitive Edge
- Verizon's C-band and mmWave spectrum holdings create a physical infrastructure moat that T-Mobile and AT&T cannot easily replicate. Spectrum is a finite, government-auctioned asset with multi-decade license durations, making it a durable competitive advantage.
- The Fios fiber network in the Northeast is a natural monopoly in many markets, competing against aging cable infrastructure. Broadband net adds of 844K in FY2025 show Verizon is winning share in fixed broadband, diversifying away from wireless-only dependence.
- Verizon's fixed wireless access (FWA) product leverages existing 5G towers to deliver home internet without new last-mile fiber builds. This capital-light broadband expansion explains the 785% surge in business wireline broadband connections in FY2025.
- Wireless telecom has the highest switching costs of any consumer service. Number portability helps, but family plans, device financing, bundled discounts, and network-specific device subsidies create multi-year lock-in that sustains pricing power.
By the Numbers
- FCF yield of 11% with FCF-to-net-income conversion of 1.14x signals high earnings quality. Cash earnings exceed GAAP earnings, which is rare for a capex-heavy telecom and supports the dividend's sustainability.
- PEG of 0.43 against a forward P/E of 8.9x implies the market is pricing in almost no growth, yet consensus EPS estimates show a ramp from $4.06 trailing to $4.95 in Y1 and $6.55 by Y5, a 10%+ CAGR. That gap is mispricing if estimates hold.
- Consumer broadband connections grew from 6.99M in FY2021 to 10.86M in FY2025, a 55% increase over four years. This is Verizon's highest-growth subscriber base and carries better unit economics than legacy wireline, shifting the revenue quality mix.
- Consumer ARPA grew from $122.30 to $138.25 over FY2021-FY2024, a 13% cumulative increase, while postpaid churn improved from 1.67% to 1.62%. Pricing power with declining churn is the hallmark of a sticky customer base.
- Capex-to-depreciation ratio of 0.91x means Verizon is now spending less on capex than it depreciates, suggesting the peak 5G/C-band investment cycle is behind it. This should structurally expand FCF going forward even without revenue acceleration.
Risk Factors
- Net debt of $187.5B at 3.2x EBITDA with a current ratio of only 0.64 and cash ratio of 0.12 leaves almost no liquidity buffer. At current FCF of ~$20B, it would take over 9 years to pay off net debt, limiting financial flexibility.
- Business segment revenue has declined every year since FY2022, from $31.1B to $29.1B, a cumulative 6.5% erosion. Business operating income fell from $3.4B to $2.1B before a partial recovery to $2.5B. This segment is structurally shrinking.
- Tangible book value per share is negative $23.00, driven by intangibles comprising 48% of total assets. If spectrum valuations or goodwill face impairment, the P/B of 1.78x could be masking significant balance sheet fragility.
- Consumer wireless postpaid net additions decelerated sharply from 2.04M in FY2023 to 1.35M in FY2024 to just 581K in FY2025. The subscriber growth engine is clearly losing momentum, which will pressure future revenue growth.
- Debt paydown yield is negative 6%, meaning Verizon is adding debt, not reducing it. Combined with the 5.4% dividend yield and 1.4% buyback yield, total shareholder yield of 1.5% is misleadingly low once you net out the debt increase.
Medtronic plc (NYSE: MDT)
$83.21
Overall Grade6.1 / 10
Medtronic plc is a global medical technology company founded in 1949 that develops and manufactures innovative therapies and devices for the health care sector. It operates across multiple therapeutic areas with a core focus on improving patient outcomes and quality of life...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E22.3
P/B2.2
P/S2.9
P/FCF19.7
FCF Yield+5.1%
Growth & Outlook
Rev Growth (YoY)+4.6%
EPS Growth (YoY)+0.5%
Revenue 5yr+2.7%
EPS 5yr+1.5%
FCF 5yr-2.0%
Fundamentals
Market Cap$106.5B
Dividend Yield3.5%
Operating Margin+17.8%
ROE+9.8%
Interest Coverage9.0x
Competitive Edge
- Medtronic's installed base of cardiac devices creates recurring revenue through replacements and monitoring services. Switching costs are extreme in implantable devices since hospitals standardize on one vendor's ecosystem for training, inventory, and follow-up protocols.
- The MiniMed 780G automated insulin delivery system has regained competitive footing against Insulet's Omnipod 5 and Tandem's t:slim, evidenced by two consecutive years of 10%+ diabetes organic growth after years of share loss.
- Regulatory moats in Class III medical devices are among the deepest in healthcare. FDA PMA approvals take years and cost hundreds of millions, creating durable barriers that protect Medtronic's 50%+ share in spinal implants and cardiac rhythm management.
- Geographic diversification is genuine: 47% U.S., 28% non-U.S. developed, 17% emerging markets. Emerging markets grew 6.5% in FY2025 and represent a long runway as procedure volumes in China, India, and Latin America expand.
- Hugo robotic-assisted surgery platform positions Medtronic against Intuitive Surgical's da Vinci monopoly. While still early, Medtronic's existing surgical instrument distribution and hospital relationships give it a credible path to adoption.
By the Numbers
- Forward P/E of 13.7x vs trailing 21.6x implies a 60% EPS jump from $3.73 to ~$5.98, and the PEG of 0.23 suggests the market is dramatically underpricing the earnings inflection relative to growth expectations.
- FCF-to-net-income conversion of 1.12x signals high earnings quality. OCF-to-net-income of 1.52x confirms cash generation well exceeds reported profits, with capex-to-depreciation at just 0.64x, meaning the asset base is being harvested efficiently.
- Diabetes segment operating profit surged 24.6% YoY on 10.7% revenue growth, indicating significant operating leverage as the MiniMed 780G gains traction. This segment's organic growth of 11.5% is the fastest across all four divisions.
- Net debt is zero and interest coverage sits at 13.2x, giving Medtronic a Debt grade of 9/10. Total shareholder yield of 5.2% (3.4% dividend, 0.5% buyback, 1.1% debt paydown) is well covered by 5.3% FCF yield.
- Cardiovascular organic growth accelerated from 4% in FY2023 to 5% in FY2024 to 6.3% in FY2025, with the most recent quarter hitting 10.6% organic growth, a clear inflection driven by Cardiac Rhythm and Structural Heart.
Risk Factors
- Medical Surgical organic growth collapsed from 4.7% in FY2024 to 0.8% in FY2025, and segment operating profit fell 4% YoY despite flat revenue. This $8.4B segment (23% of revenue) is a margin drag with no clear recovery catalyst.
- The 76% earnings payout ratio is stretched for a company growing EPS at just 0.5% YoY. If forward estimates disappoint, the dividend consumes nearly all earnings, leaving minimal reinvestment buffer.
- Five-year FCF CAGR is negative at -2.0%, and 10-year FCF CAGR is -2.3%, even as revenue grew. FCF per share of $4.21 has been structurally declining, masked by the recent one-year uptick of 1.5%.
- SGA-to-revenue at 32.4% is high for a medtech company at this scale. Despite $36B in revenue, Medtronic has not meaningfully leveraged its cost structure, with operating margin stuck near 17.8% for years.
- Revenue estimates show a dip from $38.9B in Y1 to $38.2B in Y2 before recovering, suggesting analysts see near-term headwinds. EPS growth from Y1 ($5.98) to Y2 ($6.05) is just 1.2%, implying very limited operating leverage.
Brookfield Asset Management Ltd. (NYSE: BAM)
$46.35
Overall Grade5.9 / 10
Brookfield Asset Management Ltd. operates as one of the world's largest alternative asset managers, providing investment products to institutional and retail clients globally, including pension plans, sovereign wealth funds, and endowments...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E31.5
P/B9.4
P/S14.0
P/FCF30.7
FCF Yield+3.3%
Growth & Outlook
Rev Growth (YoY)+5.3%
EPS Growth (YoY)-7.0%
Revenue 5yr+10.4%
EPS 5yr-
FCF 5yr+14.2%
Fundamentals
Market Cap$104.3B
Dividend Yield4.3%
Operating Margin+62.7%
ROE+23.0%
Interest Coverage21.3x
Competitive Edge
- BAM manages ~$1 trillion in AUM across real assets (infrastructure, renewables, real estate, credit). This diversification across uncorrelated alternative strategies creates fee stability that pure-play PE firms like KKR or Apollo lack.
- Brookfield's vertically integrated operating model, where BN operates the assets BAM raises capital for, creates a self-reinforcing flywheel. Strong operating track records drive fundraising, which drives fees, which funds further capability building.
- The secular shift of institutional allocations toward alternatives (from ~5% to 15-20% of portfolios) is still in early innings. BAM is positioned as one of only 4-5 managers globally with scale across infrastructure, credit, and transition investing.
- BAM's insurance channel through Brookfield Reinsurance provides a permanent, low-cost capital source that competitors like Blackstone (via BXPE) are still building. This annuitizes fee streams and reduces fundraising cyclicality.
- Switching costs in alternative asset management are extremely high. LPs commit capital for 10-15 year fund lives, creating locked-in fee streams. Re-ups from existing LPs typically exceed 70%, making the revenue base inherently sticky.
By the Numbers
- Profitability grade of 9.8/10 is exceptional and consistent with BAM's asset-light fee model. Estimated EBIT margins run ~65% across Y1-Y4 estimates ($4.06B EBIT on $6.25B revenue Y1), confirming the business generates income primarily from management fees with minimal capital deployment.
- Consensus EPS growth trajectory is strong: $1.86 (Y1) to $2.59 (Y3), implying a ~18% EPS CAGR over three years. At $45.50, the Y3 forward P/E compresses to ~17.6x, which is cheap for a compounder with 65% EBIT margins.
- Revenue estimates show 17% growth from Y1 to Y2 ($6.25B to $7.32B), then moderate to ~10% in Y3. This acceleration-then-plateau pattern suggests a large fundraising vintage closing in the near term, pulling forward fee recognition.
- Debt grade at 7.6/10 is reassuring for a financial services firm. Post-spinoff BAM was deliberately structured as the asset-light entity, carrying minimal balance sheet risk compared to parent BN's infrastructure and real estate obligations.
Risk Factors
- Valuation grade of 2.5/10 is a clear warning. At ~24.5x Y1 EPS, the stock prices in significant growth, yet the growth grade is only 3.9/10. This disconnect suggests the market is paying a premium for growth that hasn't yet materialized in historical results.
- Shareholder grade of 2.3/10 is the weakest metric. As a recently spun-off entity (Dec 2022), BAM has limited capital return history. Dividend and buyback programs are nascent, meaning shareholders rely almost entirely on price appreciation.
- Returns grade at 2.7/10 conflicts sharply with the 9.8 profitability score. This likely reflects that while margins are excellent, returns on equity or invested capital are suppressed by the large goodwill and intangible base carried from the spinoff structure.
- Y4 revenue estimate ($7.89B) actually declines from Y3 ($8.04B), a rare pattern. This could signal analysts expect a fundraising gap between vintage cycles, creating fee revenue lumpiness that the market may not be pricing correctly.
- Only 8-9 analysts cover the stock. Thin coverage for a $70B+ market cap company increases the risk of estimate clustering and delayed consensus revisions when fundamentals shift.
The Progressive Corporation (NYSE: PGR)
$213.83
Overall Grade5.8 / 10
The Progressive Corporation is one of the largest property and casualty insurance providers in the United States, widely recognized for its personal and commercial auto insurance products. The company operates through three primary segments: Personal Lines, Commercial Lines, and Property...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E11.0
P/B-
P/S1.4
P/FCF-
FCF Yield+0.0%
Growth & Outlook
Rev Growth (YoY)+3.9%
EPS Growth (YoY)+3.7%
Revenue 5yr+13.8%
EPS 5yr+28.5%
FCF 5yr+17.3%
Fundamentals
Market Cap$124.9B
Dividend Yield6.5%
Operating Margin+16.6%
ROE+36.2%
Interest Coverage50.8x
Competitive Edge
- Progressive's direct-to-consumer distribution model and Snapshot telematics program create a structural cost advantage over agency-dependent competitors like Allstate and Travelers, enabling profitable growth at lower combined ratios.
- The bundling strategy through the Progressive Advantage Agency and HomeQuote Explorer creates switching costs. Once a customer bundles auto and home, retention rates jump significantly, reducing acquisition cost amortization periods.
- Progressive's pricing algorithm sophistication, built on decades of granular driving data and real-time telematics, allows faster and more accurate rate adjustments than peers. This was the key advantage during the 2022-2023 inflation shock when competitors mispriced risk.
- The company's willingness to shrink during unprofitable periods (as seen in prior soft markets) and grow aggressively when pricing is favorable demonstrates rare capital allocation discipline in an industry prone to cycle-chasing.
- Progressive is the #1 commercial auto insurer in the U.S. for small fleets, a segment with high barriers to entry due to underwriting complexity. This niche dominance provides a stable earnings base separate from the competitive personal auto market.
By the Numbers
- Combined ratio improved from 95.8 in FY2022 to 88.8 in FY2024 and 87.4 YTD FY2025, a 840bps improvement driven by loss ratio compression from 77.3 to 65.9. This is elite underwriting discipline, well below the industry breakeven of ~100.
- Total Personal Lines net premiums written grew 23.5% in FY2024 and 14.3% YTD FY2025, reaching $72.6B. Progressive is taking massive market share while simultaneously improving profitability, a rare combination in P&C insurance.
- Personal Lines pre-tax profit exploded from $1.27B in FY2022 to $6.84B in FY2024, a 440% increase over two years, while premiums grew ~52% over the same period. Operating leverage on the underwriting book is extraordinary.
- Interest coverage at 50.8x signals near-irrelevant debt burden relative to earnings power. With trailing EBIT of $14.5B against what is likely ~$285M in interest expense, the balance sheet is a non-issue.
- ROE of 36.2% alongside ROA of 9.6% shows returns are driven by genuine operating performance, not just financial leverage. For an insurer, 9.6% ROA is exceptional and reflects the quality of the underwriting book.
Risk Factors
- Consensus EPS estimates decline from $19.23 trailing to $17.50 (Y1), $16.21 (Y2), and $16.08 (Y3), implying a 16% earnings decline over three years. The market is pricing in combined ratio normalization and the end of the hard pricing cycle.
- Underwriting expense ratio has risen from 17.3 in FY2023 to 19.7 in FY2024 to 21.5 YTD FY2025, a 240bps increase. Advertising and customer acquisition costs are climbing as growth moderates, partially offsetting loss ratio gains.
- Commercial Lines net premiums written turned negative at -3.1% YoY in FY2025 after years of 8-17% growth. This segment, roughly 13% of premiums, may be hitting pricing resistance or competitive pressure from specialty carriers.
- P/B ratio is negative at -114x, meaning book value is negative. For an insurer where book value is a core valuation anchor, this signals the balance sheet has been aggressively leveraged through shareholder returns or unrealized losses on the bond portfolio.
- FCF yield shows as 0% despite $11.9B in unlevered FCF, and FCF-to-net-income conversion is reported at zero. The cash flow statement for insurers is noisy, but the disconnect between $11.9B unlevered FCF and zero reported FCF metrics warrants scrutiny on reserve movements.
Chevron Corporation (NYSE: CVX)
$194.79
Overall Grade5.1 / 10
Chevron Corporation is a leading integrated energy and chemicals company with operations spanning the globe. The company's business is divided into two primary segments: Upstream and Downstream...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E35.9
P/B2.2
P/S2.2
P/FCF29.9
FCF Yield+3.3%
Growth & Outlook
Rev Growth (YoY)+0.8%
EPS Growth (YoY)-13.0%
Revenue 5yr+3.6%
EPS 5yr-6.7%
FCF 5yr-13.0%
Fundamentals
Market Cap$387.9B
Dividend Yield3.7%
Operating Margin+8.2%
ROE+5.9%
Interest Coverage11.3x
Competitive Edge
- The Hess acquisition gives Chevron a 30% stake in Guyana's Stabroek block, one of the highest-return oil developments globally with breakeven below $35/bbl. This is a multi-decade reserve addition that few peers can replicate organically.
- Chevron's Permian Basin position (over 2M net acres) provides low-decline, short-cycle production that can flex with commodity prices. Unlike deepwater or LNG, Permian wells generate returns within 12-18 months, giving management real-time capital allocation optionality.
- Integrated model with downstream refining provides a natural hedge: when crude falls, refining margins often expand (as seen in FY2025 downstream recovery of +75% YoY). This counter-cyclicality smooths cash flows versus pure-play E&Ps.
- Chevron's LNG portfolio (Gorgon, Wheatstone, equity in global projects) positions it for structural gas demand growth in Asia. Long-term LNG contracts provide revenue visibility that crude oil spot exposure cannot.
- Minimal goodwill at 1.4% of assets means the balance sheet carries almost no impairment risk from prior acquisitions. This is unusual for a company that just completed a $53B deal and reflects Hess being booked largely at fair value of tangible assets.
By the Numbers
- Total upstream production grew 11.5% YoY to 3,723 MBOED in FY2025, with U.S. production surging 16.2% to 1,858 MBOED. This volume growth is masking commodity price weakness and reflects the Hess acquisition contribution flowing through.
- Forward P/E of 13.75x versus trailing P/E of 33.8x implies consensus expects earnings to more than double, with est. EPS Y1 at $14.17 versus trailing $6.63. The PEG ratio of 0.09 suggests the market is pricing in almost no growth premium for this earnings recovery.
- Capex-to-depreciation ratio of 0.80x means Chevron is spending less on capex than it depreciates, effectively harvesting its asset base. This is unusual for a company growing production 11.5% and suggests acquired Hess assets are driving volume without proportional reinvestment.
- SG&A-to-revenue of just 2.67% is among the lowest in integrated oils, indicating extreme overhead efficiency. Combined with interest coverage of 27.5x, the fixed cost structure provides significant downside protection in a commodity downturn.
- Total shareholder yield of 4.63% (3.37% dividend plus 2.47% buyback minus 1.41% debt increase) remains competitive. The $12.1B in TTM buybacks is meaningful capital return even as the company absorbs Hess-related debt.
Risk Factors
- Payout ratio of 120.7% on trailing earnings means Chevron is paying more in dividends than it earns, with FCF payout at 96.8%. At $6.97/share dividend versus $7.20 FCF/share, there is virtually zero cushion if oil prices weaken further.
- Upstream international segment earnings fell 36.3% YoY to $7.0B in FY2025 despite production growing 7.2%. This implies realized pricing collapsed roughly 40%, revealing how exposed international upstream is to Brent weakness and fiscal regime changes.
- FCF conversion is deteriorating: FCF-to-OCF ratio of 44.1% means 56% of operating cash flow is consumed by capex. Upstream capex grew 10.9% YoY to $15.9B while upstream earnings fell 31.1%, a troubling divergence between investment and returns.
- Shares outstanding grew 3.1% YoY despite $12.1B in buybacks, meaning the Hess acquisition dilution overwhelmed repurchase activity. Revenue per share of $97.15 is essentially flat, confirming dilution is eating into per-share economics.
- Quick ratio of 0.73x and cash per share of just $2.78 signal tight near-term liquidity. With $45.4B total debt and net debt/EBITDA at 1.08x (up from near-zero pre-Hess), the balance sheet has meaningfully less flexibility than two years ago.
International Business Machines Corporation (NYSE: IBM)
$214.19
Overall Grade5.0 / 10
International Business Machines Corporation (IBM) is a global technology and consulting leader that assists enterprises in their digital transformations. The company operates through four primary business segments: Software, Consulting, Infrastructure, and Financing...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E21.4
P/B6.9
P/S3.3
P/FCF17.6
FCF Yield+5.7%
Growth & Outlook
Rev Growth (YoY)+2.0%
EPS Growth (YoY)+1.3%
Revenue 5yr+3.7%
EPS 5yr+16.8%
FCF 5yr+6.7%
Fundamentals
Market Cap$201.8B
Dividend Yield3.2%
Operating Margin+18.2%
ROE+32.6%
Interest Coverage6.4x
Competitive Edge
- IBM's mainframe installed base creates a durable lock-in: migrating off z/OS is a multi-year, multi-hundred-million-dollar project for large banks and insurers. Transaction Processing revenue grew 8.7% in FY2024, proving pricing power in a supposedly declining category.
- The watsonx AI platform is differentiated by targeting regulated industries (banking, healthcare, government) where data sovereignty and auditability matter. This avoids direct competition with hyperscalers selling commodity AI inference to tech-native companies.
- Red Hat's hybrid cloud position benefits from enterprise reluctance to go all-in on a single hyperscaler. Multi-cloud orchestration is a structural need, not a trend, and OpenShift has no direct equivalent from AWS, Azure, or GCP.
- IBM's consulting arm serves as a distribution channel for its software, creating a flywheel: consultants embed IBM software into client architectures, generating recurring license and subscription revenue with high switching costs.
- Federal and defense contracts provide revenue stability with long procurement cycles. IBM's FedRAMP authorizations and security clearances are barriers that take competitors years to replicate.
By the Numbers
- Software segment income grew 14.2% YoY on 10.6% revenue growth in FY2025, with gross margins at 83.5%. This operating leverage means each incremental software dollar drops more profit, and software now represents 44% of total revenue, up from 41% two years ago.
- FCF-to-net-income ratio of 1.09x confirms high earnings quality. Unlike many IT services peers where restructuring charges and acquisition amortization create gaps between GAAP and cash, IBM's cash generation actually exceeds reported earnings.
- Infrastructure segment income surged 41.1% YoY on just 12.1% revenue growth, with gross margins expanding 280bps to 58.6%. This signals a new z16/LinuxONE cycle is hitting peak profitability, a pattern that repeats every 2-3 years with mainframe refreshes.
- SBC at 2.6% of revenue is well below the IT services peer average of 4-6%, meaning IBM's reported margins face less inflation from non-cash compensation. TTM SBC of $1.8B is modest relative to $11.7B in trailing FCF.
- Consulting gross margins improved for the fourth consecutive year to 28.1%, up from 25.5% in FY2022. Combined with the 20% jump in segment income on just 1.8% revenue growth, this shows real cost discipline rather than top-line-driven profit growth.
Risk Factors
- Consulting signings fell 13.2% YoY to $21.8B and book-to-bill dropped to 1.03x from 1.21x. This is a leading indicator: consulting revenue growth of 1.8% will likely decelerate further in coming quarters as the backlog thins.
- Payout ratio at 87.9% of earnings and 82.4% of FCF leaves almost no margin of safety for the $10.11/share dividend. With net debt of $58B and only $11.7B in trailing FCF, any earnings hiccup forces a choice between dividend and deleveraging.
- Tangible book value per share is negative $59.30, driven by goodwill and intangibles at 57% of total assets. This acquisition-heavy balance sheet carries meaningful impairment risk if the acquired software assets (HashiCorp, Apptio, etc.) underperform.
- Revenue growth of 2% YoY and 3.7% 5Y CAGR paired with a PEG of 2.25 suggests the market is pricing in acceleration that hasn't materialized. The growth grade of 1.8/10 confirms IBM remains a low-single-digit grower despite the AI narrative.
- Current ratio of 0.80 and quick ratio of 0.54 indicate short-term liquidity is tight. With $69.8B in total debt and OCF-to-debt coverage of just 20%, IBM is dependent on capital markets access to manage maturities.
Duke Energy Corporation (NYSE: DUK)
$130.52
Overall Grade4.8 / 10
Duke Energy Corporation operates primarily through two business segments: Electric Utilities and Infrastructure, and Gas Utilities and Infrastructure. The Electric Utilities segment, which accounts for over 90% of total revenue, generates electricity using a diverse mix of coal, nuclear, natural gas, hydroelectric, and renewable energy sources...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E20.1
P/B1.9
P/S3.1
P/FCF-30.9
FCF Yield-3.2%
Growth & Outlook
Rev Growth (YoY)+2.9%
EPS Growth (YoY)+3.5%
Revenue 5yr+6.1%
EPS 5yr+6.9%
FCF 5yr-16.6%
Fundamentals
Market Cap$101.8B
Dividend Yield3.3%
Operating Margin+27.2%
ROE+9.6%
Interest Coverage2.4x
Competitive Edge
- Duke operates in six states with constructive regulatory environments, particularly North Carolina and Florida, where population growth and data center demand are creating organic load growth that supports rate base expansion without contentious rate cases.
- The Carolinas and Florida service territories sit in the path of massive data center buildouts. Duke's monopoly position means hyperscalers like AWS, Google, and Microsoft must contract with Duke, providing visibility on load growth for 10+ years.
- Regulated utility model with 90%+ revenue from electric utilities creates highly predictable earnings. Regulators effectively guarantee returns on invested capital, making the 3.95% ROIC a floor rather than a ceiling as rate base grows.
- Duke's exit from Commercial Renewables (divested FY2022) simplified the business and removed merchant power exposure. The company now captures renewable growth through regulated rate base investment, earning guaranteed returns rather than taking market risk.
- Multi-year grid modernization and storm hardening programs in Florida and the Carolinas are largely pre-approved by regulators, reducing execution risk on the $12.5B+ annual capex plan and providing earnings visibility through 2028+.
By the Numbers
- Electric Utilities segment income grew 11.9% YoY in FY2025 on only 4.5% revenue growth, showing strong operating leverage as rate base investments flow through to earnings at expanding margins.
- EPS growth 3Y CAGR of 22.6% far outpaces revenue growth 3Y CAGR of 4.5%, indicating Duke is extracting meaningful earnings expansion from its regulated rate base without needing aggressive top-line growth.
- OCF-to-net-income ratio of 2.23x is excellent for a regulated utility, confirming high earnings quality. Depreciation and deferred taxes are generating substantial non-cash cash flow above reported earnings.
- Effective tax rate of 13% is well below the statutory rate, likely driven by renewable energy tax credits and bonus depreciation on the massive $12.5B+ annual capex program, directly boosting after-tax returns.
- Electric Utilities segment income compounded from $3.85B (FY2021) to $5.34B (FY2025), a 38.6% cumulative increase, while revenue grew only 29.9% over the same period. Margin expansion is structural, not cyclical.
Risk Factors
- FCF is deeply negative at -$3.3B (FCF margin of -9.9%), and FCF growth 5Y CAGR of -43.2% shows this is worsening. The dividend is entirely funded by debt issuance, not free cash flow, as the FCF payout ratio of -101% confirms.
- Capex-to-OCF of 1.28x means Duke spends $1.28 in capex for every $1 of operating cash flow. This gap must be financed externally, and with $91.2B in total debt, the cumulative cost of this funding model is compounding.
- Net debt/EBITDA of 4.83x is elevated even for a utility. Combined with interest coverage of only 4.55x, any meaningful rise in refinancing costs on the $91B debt stack would compress earnings growth materially.
- Gas Utilities segment income dropped 12.5% in FY2024 before rebounding 23.1% in FY2025, showing earnings volatility in a segment that should be stable. The FY2025 bounce may reflect weather normalization rather than structural improvement.
- Capex-to-depreciation of 1.89x means Duke is spending nearly 2x its depreciation charge. While this signals growth investment, it also means rate base growth depends on continued regulatory approval of returns on this accelerating capital deployment.
Ten names across cybersecurity, pharma, semiconductors, specialty finance, tankers, social media, electric buses, and community banking. That’s a wild spread, and I think that’s exactly the point. If you’re a Canadian investor crossing the border for dividends, you shouldn’t be replicating what you already own. You should be filling gaps. Every name on this list exists in a corner of the market that the TSX basically doesn’t cover.
The thing I find most compelling about this group isn’t the yields. Most of them are modest. It’s the earnings momentum behind the payouts. Companies initiating or growing dividends while revenue is accelerating tell you something about how confident management is in the durability of their cash flows. That’s a fundamentally different signal than a mature utility grinding out its 30th consecutive year of $0.02 annual increases.
Pick your spots carefully, put them in the right account, and let the businesses do what they’re already doing.
